

# Effect of tight control management on Crohn's disease (controlled phase 3 trial)

Lancet, The

390, 2779-2789

DOI: [10.1016/s0140-6736\(17\)32641-7](https://doi.org/10.1016/s0140-6736(17)32641-7)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Targeting Crohn's disease. <i>Lancet, The</i> , 2017, 390, 2742-2744.	6.3	0
3	Clinical disease activity in the CALM study – Authors' reply. <i>Lancet, The</i> , 2018, 391, 1482.	6.3	2
4	Clinical disease activity in the CALM study. <i>Lancet, The</i> , 2018, 391, 1481-1482.	6.3	2
5	Residual Lesions on Capsule Endoscopy Is Associated with Postoperative Clinical Recurrence in Patients with Crohn's Disease. <i>Digestive Diseases and Sciences</i> , 2018, 63, 768-774.	1.1	12
6	Novel Therapies and Treatment Strategies for Patients with Inflammatory Bowel Disease. <i>Current Treatment Options in Gastroenterology</i> , 2018, 16, 129-146.	0.3	64
7	A Never Ending STORI. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1034-1036.	2.4	2
8	It is Time to Revise the STRIDE Guidelines Determining Therapeutic Goals for Treat-to-Target in Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 509-509.	0.6	28
9	Diffusion-weighted MRI in inflammatory bowel disease. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 433-443.	3.7	21
10	Association Between Serum Infliximab Trough Concentrations During Maintenance Therapy and Biochemical, Endoscopic, and Histologic Remission in Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 2266-2271.	0.9	65
11	Editorial: ways to reduce emergency department utilisation among IBD patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1325-1326.	1.9	0
12	Editorial: clinical trials in IBD – how much of a difference is enough?. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1032-1033.	1.9	0
13	Heterogeneity in Definitions of Efficacy and Safety Endpoints for Clinical Trials of Crohn's Disease: A Systematic Review. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1407-1419.e22.	2.4	41
14	Top-down in the Long Term in Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 513-514.	0.6	4
15	Inflammatory biomarkers improve management of Crohn's disease. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2018, 15, 4-5.	8.2	9
16	Quality of care in inflammatory bowel diseases: What is the best way to better outcomes?. <i>World Journal of Gastroenterology</i> , 2018, 24, 2363-2372.	1.4	18
19	From bench to bedside: Fecal calprotectin in inflammatory bowel diseases clinical setting. <i>World Journal of Gastroenterology</i> , 2018, 24, 3681-3694.	1.4	123
20	UEG Week 2018 Poster Presentations. <i>United European Gastroenterology Journal</i> , 2018, 6, A135.	1.6	27
21	Clinical experience of optimising thiopurine use through metabolite measurement in inflammatory bowel disease. <i>Gastroenterology &amp; Hepatology (English Edition)</i> , 2018, 41, 629-635.	0.0	2

#	ARTICLE	IF	CITATIONS
24	Capsule endoscopy: Current status and role in Crohn's disease. <i>World Journal of Gastrointestinal Endoscopy</i> , 2018, 10, 184-192.	0.4	14
25	Experiencia en práctica clínica de optimización de tiopurinas mediante determinación de sus metabolitos en la enfermedad inflamatoria intestinal. <i>Gastroenterología Y Hepatología</i> , 2018, 41, 629-635.	0.2	7
26	The role of biologics in the treatment of patients with inflammatory bowel disease. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2018, 79, 686-693.	0.2	5
27	Integrated Care for Crohn's Disease: A Plea for the Development of Clinical Decision Support Systems. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 1499-1504.	0.6	5
28	Editorial: treating strictures in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 1312-1313.	1.9	1
29	The risk for opportunistic infections in inflammatory bowel disease with biologics: an update. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018, 12, 1101-1108.	1.4	34
30	Validity of Capsule Endoscopy in Monitoring Therapeutic Interventions in Patients with Crohn's Disease. <i>Journal of Clinical Medicine</i> , 2018, 7, 311.	1.0	12
31	Reply. <i>Gastroenterology</i> , 2018, 155, 1278-1279.	0.6	0
32	Clinical course in Crohn's disease: factors associated with behaviour change and surgery. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 1222-1227.	0.6	9
33	Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the utility of the determination of faecal calprotectin in inflammatory bowel disease. <i>Gastroenterología Y Hepatología (English Edition)</i> , 2018, 41, 514-529.	0.0	2
34	Risk stratifying in real life. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 9-10.	1.4	0
36	The Role of Biomarkers in Clinical Trials of Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 1619-1623.	0.9	9
37	Editorial: Multiparametric Evaluation Predicts Different Mid-Term Outcomes in Crohn's Disease. <i>Digestive Diseases</i> , 2018, 36, 182-183.	0.8	0
38	Colorectal cancer prevention in patients with ulcerative colitis. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2018, 32-33, 103-109.	1.0	47
39	Expert opinion for use of faecal calprotectin in diagnosis and monitoring of inflammatory bowel disease in daily clinical practice. <i>United European Gastroenterology Journal</i> , 2018, 6, 1117-1125.	1.6	48
41	How to predict response to anti-tumour necrosis factor agents in inflammatory bowel disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018, 12, 797-810.	1.4	30
42	Vedolizumab and early postoperative complications in nonintestinal surgery: a case-matched analysis. <i>Therapeutic Advances in Gastroenterology</i> , 2018, 11, 175628481878361.	1.4	11
43	Real-world clinical, endoscopic and radiographic efficacy of vedolizumab for the treatment of inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 626-637.	1.9	43

#	ARTICLE	IF	CITATIONS
45	Review article: treating a target for inflammatory bowel disease-associated anaemia. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 610-617.	1.9	28
46	Evolution of Clinical Trials in Inflammatory Bowel Diseases. <i>Current Gastroenterology Reports</i> , 2018, 20, 41.	1.1	10
47	Recomendaciones del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) sobre la utilidad de la determinación de calprotectina fecal en la enfermedad inflamatoria intestinal. <i>Gastroenterología Y Hepatología</i> , 2018, 41, 514-529.	0.2	33
48	Success and safety of high infliximab trough levels in inflammatory bowel disease. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 940-946.	0.6	38
49	Changing treatment paradigms for the management of inflammatory bowel disease. <i>Korean Journal of Internal Medicine</i> , 2018, 33, 28-35.	0.7	33
50	Influence of early adalimumab serum levels on immunogenicity and long-term outcome of anti-TNF naive Crohn's disease patients: the usefulness of rapid testing. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 731-739.	1.9	62
51	Switching from originator to biosimilar infliximab – real world data of a prospective 18 months follow-up of a single-centre IBD population. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 692-699.	0.6	41
52	Crohn's disease: management in adults, children and young people – concise guidance. <i>Clinical Medicine</i> , 2018, 18, 231-236.	0.8	9
53	Smarter Care for Patients With Inflammatory Bowel Disease: A Necessity for IBD Home, Value-Based Health Care and Treat-to-Target Strategies. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 1460-1461.	0.9	6
54	Treatment Perspectives in Crohn's Disease. <i>Digestion</i> , 2018, 98, 135-142.	1.2	8
55	The current state of the art for biological therapies and new small molecules in inflammatory bowel disease. <i>Mucosal Immunology</i> , 2018, 11, 1558-1570.	2.7	80
56	Utility of proactive infliximab levels in paediatric Crohn's disease. <i>Archives of Disease in Childhood</i> , 2019, 104, 251-255.	1.0	10
57	ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 144-164K.	0.6	958
58	Association Between Level of Fecal Calprotectin and Progression of Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2269-2276.e4.	2.4	48
59	Anti-TNF biosimilars in Crohn's Disease: a patient-centric interdisciplinary approach. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 731-738.	1.4	16
60	A Treat-to-Target Update in Ulcerative Colitis: A Systematic Review. <i>American Journal of Gastroenterology</i> , 2019, 114, 874-883.	0.2	167
61	Innovations in Oral Therapies for Inflammatory Bowel Disease. <i>Drugs</i> , 2019, 79, 1321-1335.	4.9	51
62	Canadian Association of Gastroenterology Clinical Practice Guideline for the Medical Management of Pediatric Luminal Crohn's Disease. <i>Gastroenterology</i> , 2019, 157, 320-348.	0.6	49

#	ARTICLE	IF	CITATIONS
63	De-escalation of IBD Therapy: When, Who, and How?. Crohn's & Colitis 360, 2019, 1, .	0.5	1
64	Canadian Association of Gastroenterology Clinical Practice Guideline for the Medical Management of Pediatric Luminal Crohn's Disease. Journal of the Canadian Association of Gastroenterology, 2019, 2, e35-e63.	0.1	16
65	Inflammation in gastrointestinal disorders: prevalent socioeconomic factors. Clinical and Experimental Gastroenterology, 2019, Volume 12, 321-329.	1.0	16
66	Targeting mucosal healing in Crohn's disease: what the clinician needs to know. Therapeutic Advances in Gastroenterology, 2019, 12, 175628481985686.	1.4	50
67	Assessment of small bowel mucosal healing by video capsule endoscopy for the prediction of short-term and long-term risk of Crohn's disease flare: a prospective cohort study. The Lancet Gastroenterology and Hepatology, 2019, 4, 519-528.	3.7	63
68	CECDALic – a new useful tool in pan-intestinal evaluation of Crohn's disease patients in the era of mucosal healing. Scandinavian Journal of Gastroenterology, 2019, 54, 1326-1330.	0.6	12
69	The Clinical Accuracy of the BÃœHLMANN fCAL ELISA in the Differentiation of Inflammatory Bowel Disease From Irritable Bowel Syndrome: A Multicenter Prospective Case-Control Study. Crohn's & Colitis 360, 2019, 1, .	0.5	2
70	IBD prevalence in Lothian, Scotland, derived by capture-recapture methodology. Gut, 2019, 68, 1953-1960.	6.1	134
72	PREVENTION OF INFLAMMATORY BOWEL DISEASE COMPLICATIONS AND RECURRENCE. Revista Médica Clínica Las Condes, 2019, 30, 339-343.	0.2	0
73	Current Concepts of Pharmacotherapy in Crohn's Disease. Visceral Medicine, 2019, 35, 344-347.	0.5	3
74	Medical Management of Inflammatory Bowel Disease. Surgical Clinics of North America, 2019, 99, 1223-1235.	0.5	11
76	Impact of faecal calprotectin measurement on clinical decision-making in patients with Crohn's disease and ulcerative colitis. PLoS ONE, 2019, 14, e0223893.	1.1	6
77	Serum MMP-9: a novel biomarker for prediction of clinical relapse in patients with quiescent Crohn's disease, a post hoc analysis. Therapeutic Advances in Gastroenterology, 2019, 12, 175628481988159.	1.4	21
78	Remicade® (infliximab): 20 years of contributions to science and medicine. Biologics: Targets and Therapy, 2019, Volume 13, 139-178.	3.0	78
79	Proactive Monitoring of Adalimumab Trough Concentration Associated With Increased Clinical Remission in Children With Crohn's Disease Compared With Reactive Monitoring. Gastroenterology, 2019, 157, 985-996.e2.	0.6	178
80	Elevated Pretreatment Plasma Oncostatin M Is Associated With Poor Biochemical Response to Infliximab. Crohn's & Colitis 360, 2019, 1, otz026.	0.5	22
81	Current new challenges in the management of ulcerative colitis. Intestinal Research, 2019, 17, 36-44.	1.0	40
82	Comparison of fecal calprotectin and serum C-reactive protein in early prediction of outcome to infliximab induction therapy. Scandinavian Journal of Gastroenterology, 2019, 54, 1081-1088.	0.6	8

#	ARTICLE	IF	CITATIONS
83	Treat-to-Target Approach in Inflammatory Bowel Disease: The Role of Advanced Practice Providers. <i>Journal for Nurse Practitioners</i> , 2019, 15, 676-681.	0.4	11
84	Endoscopic, Radiologic, and Histologic Healing With Vedolizumab in Patients With Active Crohn's Disease. <i>Gastroenterology</i> , 2019, 157, 1007-1018.e7.	0.6	145
85	Approaches to Integrating Biomarkers Into Clinical Trials and Care Pathways as Targets for the Treatment of Inflammatory Bowel Diseases. <i>Gastroenterology</i> , 2019, 157, 1032-1043.e1.	0.6	48
86	British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. <i>Gut</i> , 2019, 68, s1-s106.	6.1	1,353
87	Vedolizumab Trough Levels and Histological Healing During Maintenance Therapy in Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 970-975.	0.6	32
88	Low fecal calprotectin predicts clinical remission in Crohn's disease patients: the simple answer to a challenging question. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 49-54.	0.6	6
89	Systematic Review: Cost-effective Strategies of Optimizing Anti-tumor Necrosis and Immunomodulators in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 1462-1473.	0.9	15
90	Clinical value of fecal calprotectin. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2019, 56, 307-320.	2.7	72
91	Reduction in surgical stoma rates in Crohn's disease: a population-based time trend analysis. <i>Colorectal Disease</i> , 2019, 21, 1279-1287.	0.7	12
92	Biomarkers for Remote Monitoring. , 2019, , 271-278.		1
93	Innate and Adaptive Immunology. , 2019, , 313-321.		0
94	Can Magnetic Resonance Enterography (MRE) replace ileo-colonoscopy for evaluating disease activity in Crohn's disease? <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2019, 38-39, 101621.	1.0	12
95	Barriers to anti-TNFalpha prescription among Italian physicians managing inflammatory bowel disease. <i>GastroHep</i> , 2019, 1, 93-99.	0.3	3
96	Switching to biosimilars: current perspectives in immune-mediated inflammatory diseases. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 1001-1014.	1.4	18
97	Fecal calprotectin is significantly linked to azathioprine metabolite concentrations in Crohn's disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 99-108.	0.8	3
98	Maneuvering Clinical Pathways for Crohn's Disease. <i>Current Gastroenterology Reports</i> , 2019, 21, 20.	1.1	4
99	Head-to-head comparison of three stool calprotectin tests for home use. <i>PLoS ONE</i> , 2019, 14, e0214751.	1.1	38
100	Treat-to-Target in Inflammatory Bowel Diseases, What Is the Target and How Do We Treat?. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2019, 29, 421-436.	0.6	39

#	ARTICLE	IF	CITATIONS
101	Diagnostic pathways in Crohn's disease. <i>Clinical Radiology</i> , 2019, 74, 578-591.	0.5	10
102	Why do we need to improve monitoring of patients with inflammatory bowel disease (IBD) on biologic treatment?. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 907-918.	1.4	6
104	Mucosal healing in inflammatory bowel disease: Expanding horizon. <i>Indian Journal of Gastroenterology</i> , 2019, 38, 98-109.	0.7	3
105	US Practice Patterns and Impact of Monitoring for Mucosal Inflammation After Biologic Initiation in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 1828-1837.	0.9	34
106	Predicting and preventing complications in children with inflammatory bowel disease. <i>Translational Pediatrics</i> , 2019, 8, 70-76.	0.5	9
107	Anti-TNF treatment failure: drug levels, immunogenicity, or both?. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 326-327.	3.7	3
109	Early Initiation of Anti-TNF is Associated with Favourable Long-term Outcome in Crohn's Disease: 10-Year-Follow-up Data from the Swiss IBD Cohort Study. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 1292-1301.	0.6	37
110	Prediction of treatment outcome and relapse in inflammatory bowel disease. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 667-677.	1.3	15
112	Biological Therapies in Immune-Mediated Inflammatory Diseases: Can Biosimilars Reduce Access Inequities?. <i>Frontiers in Pharmacology</i> , 2019, 10, 279.	1.6	89
113	Market Access Analysis of Biologics and Small-Molecule Inhibitors for Inflammatory Bowel Disease Among US Health Insurance Policies. <i>Digestive Diseases and Sciences</i> , 2019, 64, 2478-2488.	1.1	9
114	What is the role of C-reactive protein and fecal calprotectin in evaluating Crohn's disease activity?. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2019, 38-39, 101602.	1.0	19
115	Evolution of treatment targets in Crohn's disease. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2019, 38-39, 101599.	1.0	4
118	Quality of Care in Patients With Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 479-489.	0.9	17
119	Combination of colonoscopy and magnetic resonance enterography is more useful for clinical decision making than colonoscopy alone in patients with complicated Crohn's disease. <i>PLoS ONE</i> , 2019, 14, e0212404.	1.1	9
120	Mucosal Healing Is Associated With the Reduced Disabling Disease in Crohn's Disease. <i>Clinical and Translational Gastroenterology</i> , 2019, 10, e00015.	1.3	13
121	The effects of proactive therapeutic drug monitoring vs reactive therapeutic drug monitoring in a virtual biologic clinic, a retrospective cohort study. <i>GastroHep</i> , 2019, 1, 274-283.	0.3	4
122	The Accuracy of a Home-performed Faecal Calprotectin Test in Paediatric Patients With Inflammatory Bowel Disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2019, 69, 75-81.	0.9	2
123	Pharmacodynamic Monitoring of Biological Therapies in Chronic Inflammatory Diseases. <i>Therapeutic Drug Monitoring</i> , 2019, 41, 131-141.	1.0	6

#	ARTICLE	IF	CITATIONS
124	Noninvasive Methods For Assessing Inflammatory Bowel Disease Activity in Pregnancy. <i>Journal of Clinical Gastroenterology</i> , 2019, 53, 574-581.	1.1	33
125	Infliximab trough levels are decreasing over time in patients with inflammatory bowel disease on maintenance treatment with infliximab. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 187-191.	0.8	12
126	UEG Week 2019 Poster Presentations. <i>United European Gastroenterology Journal</i> , 2019, 7, 189-1030.	1.6	6
127	Magnetic resonance enterography, colonoscopy, and fecal calprotectin correlate in colonic Crohn's disease. <i>BMC Gastroenterology</i> , 2019, 19, 210.	0.8	11
128	A novel surgical predictive model for Chinese Crohn's disease patients. <i>Medicine (United States)</i> , 2019, 98, e17510.	0.4	16
129	Time to Reach Target Calprotectin Level in Newly Diagnosed Patients With Inflammatory Bowel Disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2019, 69, 466-473.	0.9	17
131	IBDoc Canadian User Performance Evaluation. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 1107-1114.	0.9	8
132	Differences in the imaging of Crohn's disease patients between North America and Europe: are we ready to bridge the divide?. <i>Abdominal Radiology</i> , 2019, 44, 1637-1643.	1.0	3
133	Real-World Success of Biologic Therapy in IBD: No More Reasons to Be Anti Antibody. <i>Digestive Diseases and Sciences</i> , 2019, 64, 614-615.	1.1	3
134	Quality of Care Standards in Inflammatory Bowel Disease: A Systematic Review. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 127-137.	0.6	43
135	A Treat to Target Strategy Using Panenteric Capsule Endoscopy in Pediatric Patients With Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2060-2067.e1.	2.4	39
136	How Can We Assess Complete Healing Beyond Endoscopic Remission?. <i>Inflammatory Bowel Diseases</i> , 2019, 25, e68-e68.	0.9	0
137	New approaches along the IBD course: diet, tight control and stem cells. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 82-84.	8.2	14
138	Update on C-reactive protein and fecal calprotectin: are they accurate measures of disease activity in Crohn's disease?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 319-330.	1.4	37
139	The Use of Actigraphy Differentiates Sleep Disturbances in Active and Inactive Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 1044-1053.	0.9	15
140	Retention Rate, Persistence and Safety of Adalimumab in Inflammatory Bowel Disease: A Real-Life, 9-Year, Single-Center Experience in Italy. <i>Digestive Diseases and Sciences</i> , 2019, 64, 863-874.	1.1	8
141	GlycA, a Nuclear Magnetic Resonance Spectroscopy Measure for Protein Glycosylation, is a Viable Biomarker for Disease Activity in IBD. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 389-394.	0.6	32
142	Development and Validation of Risk Matrices Concerning Ulcerative Colitis Outcomes Bayesian Network Analysis. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 401-409.	0.6	17



#	ARTICLE	IF	CITATIONS
143	Higher Adalimumab Drug Levels During Maintenance Therapy for Crohn's Disease Are Associated With Biologic Remission. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 1036-1043.	0.9	19
144	Highlights from the literature: inflammatory bowel disease. <i>Frontline Gastroenterology</i> , 2019, 10, 88-88.	0.9	0
145	Guideline recommendations for treatment of patients with inflammatory bowel diseases are not implemented in clinical practice—results of a non-representative survey. <i>International Journal of Colorectal Disease</i> , 2019, 34, 431-440.	1.0	2
146	Efficacy of Therapeutic Intervention for Patients With an Ulcerative Colitis Mayo Endoscopic Score of 1. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 782-788.	0.9	23
147	Introduction of anti-TNF therapy has not yielded expected declines in hospitalisation and intestinal resection rates in inflammatory bowel diseases: a population-based interrupted time series study. <i>Gut</i> , 2020, 69, 274-282.	6.1	145
148	Calprotectin instability may lead to undertreatment in children with IBD. <i>Archives of Disease in Childhood</i> , 2020, 105, 996-998.	1.0	24
149	Assessment of frequency and reporting of design changes among clinical drug trials published in influential medical journals. <i>European Journal of Internal Medicine</i> , 2020, 71, 45-49.	1.0	5
150	Soluble Blood Markers of Mucosal Healing in Inflammatory Bowel Disease: The Future of Noninvasive Monitoring. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 961-969.	0.9	9
151	Ulcerative Colitis and Crohn's Disease Have Similar Burden and Goals for Treatment. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 14-23.	2.4	108
152	Therapeutic Drug Monitoring of Biologics During Induction to Prevent Primary Non-Response. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 542-556.	0.6	50
153	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 262-263.	2.4	1
154	Evaluating the Cost-Effectiveness of Early Compared with Late or No Biologic Treatment to Manage Crohn's Disease using Real-World Data. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 490-500.	0.6	12
155	Management of inflammatory bowel disease in children: It is time for an individualised approach. <i>Journal of Paediatrics and Child Health</i> , 2020, 56, 1677-1684.	0.4	4
156	Development and Validation of a Test to Monitor Endoscopic Activity in Patients With Crohn's Disease Based on Serum Levels of Proteins. <i>Gastroenterology</i> , 2020, 158, 515-526.e10.	0.6	65
157	Monitoring a Combination of Calprotectin and Infliximab Identifies Patients With Mucosal Healing of Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 637-646.e11.	2.4	67
158	ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 4-22.	0.6	741
159	Longitudinal Trends in the Direct Costs and Health Care Utilization Ascribable to Inflammatory Bowel Disease in the Biologic Era: Results From a Canadian Population-Based Analysis. <i>American Journal of Gastroenterology</i> , 2020, 115, 128-137.	0.2	39
160	Meta-analysis of early bowel resection versus initial medical therapy in patient's with ileocolonic Crohn's disease. <i>International Journal of Colorectal Disease</i> , 2020, 35, 501-512.	1.0	4

#	ARTICLE	IF	CITATIONS
161	DPP-4 as a Novel Biomarker for Inflammatory Bowel Disease: Is It Ready for Clinical Use?. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 1720-1721.	0.9	3
162	The HBeAg-Negative "Gray Zone" Phase: A Frequent Condition With Different Outcomes in Western and Asian Patients?. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 263-264.	2.4	5
163	Systematic Review and External Validation of Prediction Models Based on Symptoms and Biomarkers for Identifying Endoscopic Activity in Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1704-1718.	2.4	19
164	A User's Guide to De-escalating Immunomodulator and Biologic Therapy in Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1336-1345.	2.4	9
165	How Do We Treat Inflammatory Bowel Diseases to Aim For Endoscopic Remission?. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1300-1308.	2.4	19
166	New Blood Marker of Endoscopic Disease Activity "A Step Forward in Treating Crohn's Disease to Target?. <i>Gastroenterology</i> , 2020, 158, 463-465.	0.6	1
167	Histological healing: should it be considered as a new outcome for ulcerative colitis?. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 407-412.	1.4	17
168	Complete Endoscopic Healing Associated With Better Outcomes Than Partial Endoscopic Healing in Patients With Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2256-2261.	2.4	26
169	De-escalation of immunomodulator and biological therapy in inflammatory bowel disease. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 63-79.	3.7	56
170	Personalised medicine in Crohn's disease. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 80-92.	3.7	55
171	Combination Therapy of Adalimumab With an Immunomodulator Is Not More Effective Than Adalimumab Monotherapy in Children With Crohn's Disease: A Post Hoc Analysis of the PAILOT Randomized Controlled Trial. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 1627-1635.	0.9	28
172	Use of Cross-Sectional Imaging for Tight Monitoring of Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1309-1323.e4.	2.4	33
173	Pregnant women with IBD are more likely to be adherent to biologic therapies than other medications. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 544-552.	1.9	18
174	Long-Term Safety of Adalimumab in 29,967 Adult Patients From Global Clinical Trials Across Multiple Indications: An Updated Analysis. <i>Advances in Therapy</i> , 2020, 37, 364-380.	1.3	51
175	Is fecal calprotectin an accurate marker in the management of Crohn's disease?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 390-400.	1.4	40
176	Covering the Year in CGH: 2019. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 3-10.	2.4	3
177	Evolving therapeutic goals in Crohn's disease management. <i>United European Gastroenterology Journal</i> , 2020, 8, 133-139.	1.6	10
178	Pursuing therapeutic success in Crohn's disease: A matter of definition, tools and longterm outcomes. <i>European Journal of Inflammation</i> , 2020, 18, 205873922096289.	0.2	0

#	ARTICLE	IF	CITATIONS
179	Evolving Role of Thiopurines in Inflammatory Bowel Disease in the Era of Biologics and New Small Molecules. <i>Digestive Diseases and Sciences</i> , 2021, 66, 3250-3262.	1.1	5
180	Medikamentöse Therapie des Morbus Crohn. , 2020, , 229-258.		0
181	Clearing of the Clouds in Inflammatory Bowel Disease Management. <i>Digestive Diseases and Sciences</i> , 2020, 65, 3411-3417.	1.1	1
182	Monitoring vedolizumab and ustekinumab drug levels in patients with inflammatory bowel disease: hype or hope?. <i>Current Opinion in Pharmacology</i> , 2020, 55, 17-30.	1.7	23
183	Remote Monitoring Empowerment of Patients with IBDs during the SARS-CoV-2 Pandemic. <i>Healthcare (Switzerland)</i> , 2020, 8, 377.	1.0	9
184	Environmental stimuli and gut inflammation via dysbiosis in mouse and man. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 715-716.	8.2	2
185	The Sooner the Better? Cost-effectiveness of Early Biological Therapy in Patients With Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 573-574.	0.6	1
186	Diagnosis and natural history of preclinical and early inflammatory bowel disease. <i>Annals of Gastroenterology</i> , 2020, 33, 443-452.	0.4	5
187	Treat to target or "treat to clear" in inflammatory bowel diseases: one step further?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2020, 14, 807-817.	1.4	19
188	Solving the questions regarding 5-aminosalicylate formulation in the treatment of ulcerative colitis. <i>Journal of Gastroenterology</i> , 2020, 55, 1013-1022.	2.3	7
189	Inhibitors of Tumoral Necrosis Factor Alpha in Inflammatory Bowel Disease. , 2020, , .		0
190	TNF-Alpha Blockers in Inflammatory Bowel Diseases: Practical Recommendations and a User's Guide: An Update. <i>Digestion</i> , 2020, 101, 16-26.	1.2	46
191	Normalization of Fecal Calprotectin Within 12 Months of Diagnosis Is Associated With Reduced Risk of Disease Progression in Patients With Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1835-1844.e6.	2.4	26
192	Association Between Vedolizumab Levels, Anti-vedolizumab Antibodies, and Endoscopic Healing Index in a Large Population of Patients with Inflammatory Bowel Diseases. <i>Digestive Diseases and Sciences</i> , 2021, 66, 3563-3569.	1.1	3
193	Fecal Calprotectin Is Highly Effective to Detect Endoscopic Ulcerations in Crohn's Disease Regardless of Disease Location. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1008-1016.	0.9	12
194	Contemporary Risk of Surgery in Patients With Ulcerative Colitis and Crohn's Disease: A Meta-Analysis of Population-Based Cohorts. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2031-2045.e11.	2.4	121
195	Optimizing biologic therapy in IBD: how essential is therapeutic drug monitoring?. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 702-710.	8.2	57
196	Understanding Determinants of Patient Preferences Between Stool Tests and Colonoscopy for the Assessment of Disease Activity in Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2021, 66, 2564-2569.	1.1	10

#	ARTICLE	IF	CITATIONS
197	Achieving Target Infliximab Drug Concentrations Improves Blood and Fecal Neutrophil Biomarkers in Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1045-1051.	0.9	14
198	Setting up a Virtual Calprotectin Clinic in Inflammatory Bowel Diseases: Literature Review and Nancy Experience. <i>Journal of Clinical Medicine</i> , 2020, 9, 2697.	1.0	9
199	Temporal Trends in Surgical Resection Rates and Biologic Prescribing in Crohn's Disease: A Population-based Cohort Study. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 1241-1247.	0.6	21
200	Fecal calprotectin: current and future perspectives for inflammatory bowel disease treatment. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 1091-1098.	0.8	32
202	Ulcerative colitis. <i>Nature Reviews Disease Primers</i> , 2020, 6, 74.	18.1	678
203	Ultrasensitive molecular imaging of intestinal mucosal inflammation using leukocyte-mimicking particles targeted to MAdCAM-1 in mice. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	9
204	An assessment of symptom burden in inflammatory bowel diseases to develop a patient preference-weighted symptom score. <i>Quality of Life Research</i> , 2020, 29, 3387-3396.	1.5	10
205	Early Intervention in Ulcerative Colitis: Ready for Prime Time?. <i>Journal of Clinical Medicine</i> , 2020, 9, 2646.	1.0	27
206	Early Changes in Serum Albumin Predict Clinical and Endoscopic Outcomes in Patients With Ulcerative Colitis Starting Anti-TNF Treatment. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1452-1461.	0.9	14
207	De-escalation of medical therapy in inflammatory bowel disease. <i>Current Opinion in Pharmacology</i> , 2020, 55, 73-81.	1.7	4
208	Effectiveness of Dose De-escalation of Biologic Therapy in Inflammatory Bowel Disease: A Systematic Review. <i>American Journal of Gastroenterology</i> , 2020, 115, 1768-1774.	0.2	11
209	Utility of Fecal Calprotectin in Routine Clinical Practice Is Impaired by Poor Sample Return Rates. <i>Digestive Diseases and Sciences</i> , 2021, 66, 3209-3210.	1.1	2
210	The usefulness of fecal calprotectin testing in pediatric gastroenterology clinical practice. <i>Medical Principles and Practice</i> , 2020, 30, 311-319.	1.1	1
211	Economic analysis of the adoption of capsule endoscopy within the British NHS. <i>International Journal for Quality in Health Care</i> , 2020, 32, 332-341.	0.9	17
212	Serum Interleukin-6 and -8 as Predictors of Response to Vedolizumab in Inflammatory Bowel Diseases. <i>Journal of Clinical Medicine</i> , 2020, 9, 1323.	1.0	20
213	Monitoring of inflammatory bowel disease in 2019: A French consensus for clinical practice. <i>Digestive and Liver Disease</i> , 2020, 52, 704-720.	0.4	4
214	Decrease in primary but not in secondary abdominal surgery for Crohn's disease: nationwide cohort study, 1990-2014. <i>British Journal of Surgery</i> , 2020, 107, 1529-1538.	0.1	38
215	SFED recommendations for IBD endoscopy during COVID-19 pandemic: Italian and French experience. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 507-516.	8.2	16

#	ARTICLE	IF	CITATIONS
216	Early Transmural Response Assessed Using Magnetic Resonance Imaging Could Predict Sustained Clinical Remission and Prevent Bowel Damage in Patients with Crohn's Disease Treated with Anti-Tumour Necrosis Factor Therapy. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 1524-1534.	0.6	22
217	Changes in the Intestinal Microbiota of Patients with Inflammatory Bowel Disease with Clinical Remission during an 8-Week Infliximab Infusion Cycle. <i>Microorganisms</i> , 2020, 8, 874.	1.6	16
218	The treatment approach to inflammatory bowel disease in 2020. <i>Current Opinion in Gastroenterology</i> , 2020, 36, 247-256.	1.0	8
219	Treat-to-Target in Pediatric Inflammatory Bowel Disease: What Does the Evidence Say?. <i>Paediatric Drugs</i> , 2020, 22, 463-472.	1.3	8
220	Lengthening adalimumab dosing interval in quiescent Crohn's disease patients: protocol for the pragmatic randomised non-inferiority LADI study. <i>BMJ Open</i> , 2020, 10, e035326.	0.8	5
221	Tight control for Crohn's disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial. <i>Gut</i> , 2020, 69, 658-664.	6.1	21
222	Panenteric capsule endoscopy versus ileocolonoscopy plus magnetic resonance enterography in Crohn's disease: a multicentre, prospective study. <i>BMJ Open Gastroenterology</i> , 2020, 7, e000365.	1.1	42
223	Treatment to target in patients with inflammatory bowel disease. What is the evidence?. <i>Scandinavian Journal of Gastroenterology</i> , 2020, 55, 528-536.	0.6	4
224	A virtual clinic increases anti-TNF dose intensification success via a treat-to-target approach compared with standard outpatient care in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1342-1352.	1.9	11
225	Serum oncostatin M at baseline predicts mucosal healing in Crohn's disease patients treated with infliximab. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 284-291.	1.9	41
226	MicroRNA-320a Monitors Intestinal Disease Activity in Patients With Inflammatory Bowel Disease. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00134.	1.3	16
227	Is the Combination of Pharmacokinetic and Pharmacodynamic Monitoring of Infliximab-Treated Patients the Way Forward?. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2631-2632.	2.4	4
228	Efficacy and safety of methotrexate in the management of inflammatory bowel disease: A systematic review and meta-analysis of randomized, controlled trials. <i>EClinicalMedicine</i> , 2020, 20, 100271.	3.2	23
229	Combined Use of Common Fecal and Blood Markers for Detection of Endoscopically Active Inflammatory Bowel Disease. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00138.	1.3	17
230	A further 'estri(v)de' in IBD management. <i>Digestive and Liver Disease</i> , 2020, 52, 721-722.	0.4	0
231	Clinical utility of fecal calprotectin in monitoring disease activity and predicting relapse in pregnant patients with inflammatory bowel diseases. <i>European Journal of Internal Medicine</i> , 2020, 77, 105-110.	1.0	9
232	Systematic review and meta-analysis: efficacy and safety of early biologic treatment in adult and paediatric patients with Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 831-842.	1.9	58
233	Deep Remission at 1 Year Prevents Progression of Early Crohn's Disease. <i>Gastroenterology</i> , 2020, 159, 139-147.	0.6	126

#	ARTICLE	IF	CITATIONS
234	Crohn's disease. Nature Reviews Disease Primers, 2020, 6, 22.	18.1	420
235	Association of trough vedolizumab levels with clinical, biological and endoscopic outcomes during maintenance therapy in inflammatory bowel disease. Frontline Gastroenterology, 2020, 11, 117-123.	0.9	9
236	Normalization of C-Reactive Protein Predicts Better Outcome in Patients With Crohn's Disease With Mucosal Healing and Deep Remission. Clinical and Translational Gastroenterology, 2020, 11, e00135.	1.3	7
237	Objective evaluation for treat to target in Crohn's disease. Journal of Gastroenterology, 2020, 55, 579-587.	2.3	16
238	Editorial: improving precision of iron deficiency diagnosis in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2020, 52, 400-400.	1.9	1
239	Enhancing treatment success in inflammatory bowel disease: Optimising the use of anti-TNF agents and utilising their biosimilars in clinical practice. Digestive and Liver Disease, 2020, 52, 1259-1265.	0.4	7
240	The New Proactive Approach and Precision Medicine in Crohn's Disease. Biomedicines, 2020, 8, 193.	1.4	10
241	Combined Biologic and Immunomodulatory Therapy is Superior to Monotherapy for Decreasing the Risk of Inflammatory Bowel Disease-Related Complications. Journal of Crohn's and Colitis, 2020, 14, 1354-1363.	0.6	38
242	Decreased Colonic Activin Receptor-Like Kinase 1 Disrupts Epithelial Barrier Integrity in Patients With Crohn's Disease. Cellular and Molecular Gastroenterology and Hepatology, 2020, 10, 779-796.	2.3	12
243	Association of Biomarker Cutoffs and Endoscopic Outcomes in Crohn's Disease: A Post Hoc Analysis From the CALM Study. Inflammatory Bowel Diseases, 2020, 26, 1562-1571.	0.9	27
244	Faecal calprotectin is the biomarker that best distinguishes remission from different degrees of endoscopic activity in Crohn's disease. BMC Gastroenterology, 2020, 20, 35.	0.8	16
245	Outcomes and Strategies to Support a Treat-to-target Approach in Inflammatory Bowel Disease: A Systematic Review. Journal of Crohn's and Colitis, 2020, 14, 254-266.	0.6	175
246	Review article: faecal calprotectin and histologic remission in ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2020, 51, 689-698.	1.9	55
247	Maintenance of Remission Among Patients With Inflammatory Bowel Disease After Vedolizumab Discontinuation: A Multicentre Cohort Study. Journal of Crohn's and Colitis, 2020, 14, 896-903.	0.6	12
248	Preanalytical Heterogeneity in Fecal Calprotectin Measurement Needs To Be Considered for Tight Control. Clinical Gastroenterology and Hepatology, 2020, 18, 524-525.	2.4	7
249	Imaging Findings of Ileal Inflammation at Computed Tomography and Magnetic Resonance Enterography: What do They Mean When Ileoscopy and Biopsy are Negative?. Journal of Crohn's and Colitis, 2020, 14, 455-464.	0.6	23
250	Serum C-reactive protein and albumin are useful biomarkers for tight control management of Crohn's disease in Japan. Scientific Reports, 2020, 10, 511.	1.6	20
251	Assessing National Trends and Disparities in Ambulatory, Emergency Department, and Inpatient Visits for Inflammatory Bowel Disease in the United States (2005-2016). Clinical Gastroenterology and Hepatology, 2020, 18, 2500-2509.e1.	2.4	27



#	ARTICLE	IF	CITATIONS
252	The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases. <i>Drugs</i> , 2020, 80, 99-113.	4.9	58
253	Preoperative Exclusive Total Parental Nutrition is Associated with Clinical and Laboratory Remission in Severe Active Crohn's Disease—A Pilot Study. <i>Nutrients</i> , 2020, 12, 1244.	1.7	5
254	Resolution of Inflammation and Gut Repair in IBD: Translational Steps Towards Complete Mucosal Healing. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 1131-1143.	0.9	47
255	Big data in IBD: big progress for clinical practice. <i>Gut</i> , 2020, 69, 1520-1532.	6.1	121
256	Relapse From Deep Remission After Therapeutic De-escalation in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 1413-1423.	0.6	22
257	Interventions for fatigue in inflammatory bowel disease. <i>The Cochrane Library</i> , 2020, 2020, CD012005.	1.5	21
258	Head-to-head trials in inflammatory bowel disease: past, present and future. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 365-376.	8.2	37
259	Mucosal healing in Crohn's disease: new insights. <i>Expert Review of Gastroenterology and Hepatology</i> , 2020, 14, 335-345.	1.4	13
260	A Practical Guide for Faecal Calprotectin Measurement: Myths and Realities. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 152-161.	0.6	31
261	Modelling of the relationship between infliximab exposure, faecal calprotectin and endoscopic remission in patients with Crohn's disease. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 106-118.	1.1	18
262	A Phenome-Wide Analysis of Healthcare Costs Associated with Inflammatory Bowel Diseases. <i>Digestive Diseases and Sciences</i> , 2021, 66, 760-767.	1.1	12
263	Acceptability of a "treat to target" approach in inflammatory bowel disease to patients in clinical remission. <i>Frontline Gastroenterology</i> , 2021, 12, 30-38.	0.9	7
264	Development and Validation of a Clinical Decision Support Tool That Incorporates Pharmacokinetic Data to Predict Endoscopic Healing in Patients Treated With Infliximab. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1209-1217.e2.	2.4	12
265	Fecal Calprotectin May Predict Adverse Pregnancy-Related Outcomes in Patients with Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2021, 66, 1639-1649.	1.1	10
266	Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 106-122.	0.9	14
267	Use of complementary and alternative medicine and low quality of life associate with the need for psychological and psychotherapeutic interventions in inflammatory bowel disease. <i>United European Gastroenterology Journal</i> , 2021, 9, 72-81.	1.6	3
268	Wearable Devices Are Well Accepted by Patients in the Study and Management of Inflammatory Bowel Disease: A Survey Study. <i>Digestive Diseases and Sciences</i> , 2021, 66, 1836-1844.	1.1	14
269	Anxiety and Depression Leads to Anti-Tumor Necrosis Factor Discontinuation in Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1200-1208.e1.	2.4	18

#	ARTICLE	IF	CITATIONS
270	Bowel contrast-enhanced ultrasound perfusion imaging in the evaluation of Crohn's disease patients undergoing anti-TNF± therapy. <i>Digestive and Liver Disease</i> , 2021, 53, 729-737.	0.4	11
271	Does anti-tumor necrosis factor alpha prevent the recurrence of Crohn's disease? Systematic review and meta-analysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 864-872.	1.4	7
272	The Medical Management of Paediatric Crohn's Disease: an ECCO-ESPGHAN Guideline Update. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 171-194.	0.6	265
273	Serum proteomic profiling at diagnosis predicts clinical course, and need for intensification of treatment in inflammatory bowel disease. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 699-708.	0.6	36
274	Opioid Use Among Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 895-907.e4.	2.4	22
275	Fecal calprotectin levels in COVID-19: Lessons from a systematic review on its use in inflammatory bowel disease during the pandemic. <i>Digestive and Liver Disease</i> , 2021, 53, 295-297.	0.4	13
276	Combined evaluation of fecal calprotectin and C-reactive protein as a therapeutic target in the management of patients with Crohn's disease. <i>Gastroenterology &amp; Hepatology</i> , 2021, 44, 87-95.	0.2	3
277	Panenteric capsule endoscopy identifies proximal small bowel disease guiding upstaging and treatment intensification in Crohn's disease: A European multicentre observational cohort study. <i>United European Gastroenterology Journal</i> , 2021, 9, 248-255.	1.6	32
278	Mucosal Inflammatory and Wound Healing Gene Programmes Reveal Targets for Stricturing Behaviour in Paediatric Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 273-286.	0.6	20
279	Week 6 Calprotectin Best Predicts Likelihood of Long-term Endoscopic Healing in Crohn's Disease: A Post-hoc Analysis of the UNITI/IM-UNITI Trials. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 462-470.	0.6	16
280	Decreasing Trends in Intestinal Resection and Re-Resection in Crohn's Disease. <i>Annals of Surgery</i> , 2021, 273, 557-563.	2.1	21
281	Current noninvasive modalities in Crohn's disease monitoring. <i>Annals of Gastroenterology</i> , 2021, 34, 770-780.	0.4	1
282	Digital health in the era of personalized healthcare. , 2021, , 7-31.		10
283	Second Mexican consensus on biologic therapy and small-molecule inhibitors in inflammatory bowel disease. <i>Revista De Gastroenterología De México (English Edition)</i> , 2021, 86, 70-85.	0.1	0
285	Timely Monitoring of Inflammation by Fecal Lactoferrin Rapidly Predicts Therapeutic Response in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1237-1247.	0.9	7
286	OUP accepted manuscript. <i>Journal of Crohn's and Colitis</i> , 2021, , .	0.6	1
287	A watchful waiting approach for newly diagnosed Crohn's disease patients with an inflammatory phenotype. <i>International Journal of Colorectal Disease</i> , 2021, 36, 735-743.	1.0	0
288	Informed consent in inflammatory bowel disease: a necessity in real-world clinical practice. <i>Annals of Gastroenterology</i> , 2021, 34, 466-475.	0.4	1



#	ARTICLE	IF	CITATIONS
289	Ulcerative Colitis Diagnosis and Management: Past, Present, and Future Directions. <i>Clinical Gastroenterology</i> , 2021, , 61-88.	0.0	1
290	Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110066.	1.4	34
291	Combined evaluation of fecal calprotectin and C-reactive protein as a therapeutic target in the management of patients with Crohn's disease. <i>GastroenterologÅa Y HepatologÅa (English Edition)</i> , 2021, 44, 87-95.	0.0	0
292	Costs of electronic health vs. standard care management of inflammatory bowel disease across three years of follow-upâ€”a Danish register-based study. <i>Scandinavian Journal of Gastroenterology</i> , 2021, 56, 520-529.	0.6	4
293	Medical and Endoscopic Management of Crohn Disease. <i>Topics in Magnetic Resonance Imaging</i> , 2021, 30, 43-61.	0.7	0
294	The Placebo and Nocebo Responses in Clinical Trials in Inflammatory Bowel Diseases. <i>Frontiers in Pharmacology</i> , 2021, 12, 641436.	1.6	13
295	Patient perceptions of current and potential inflammatory bowel disease diagnostic and monitoring tests. <i>Internal Medicine Journal</i> , 2022, 52, 1196-1202.	0.5	2
296	Results of the Seventh Scientific Workshop of ECCO: Precision Medicine in IBDâ€”Disease Outcome and Response to Therapy. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 1431-1442.	0.6	39
297	Practical insights into stomas in inflammatory bowel disease: what every healthcare provider needs to know. <i>Current Opinion in Gastroenterology</i> , 2021, 37, 320-327.	1.0	4
298	Results of the Seventh Scientific Workshop of ECCO: Precision Medicine in IBDâ€”Prediction and Prevention of Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 1443-1454.	0.6	33
299	New Paradigms to Help Decisions in Treatment Choice: Head to Head Trial of Biological Therapies in Inflammatory Bowel Diseases. <i>Current Drug Targets</i> , 2021, 22, 370-378.	1.0	1
300	Proactive therapeutic drug monitoring is more effective than conventional management in inducing fecal calprotectin remission in inflammatory bowel disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, 1539-1546.	0.8	10
301	The Use of Readily Available Longitudinal Data to Predict the Likelihood of Surgery in Crohn Disease. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1328-1334.	0.9	6
302	Dialing Back M for Monoclonal: Successful De-escalation of Dose-Intensified Anti-tumor Necrosis Factor Therapy in Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2022, 67, 8-10.	1.1	2
303	Serum biomarkers confirming stable remission in inflammatory bowel disease. <i>Scientific Reports</i> , 2021, 11, 6690.	1.6	25
304	Treat-to-target approach in the management of inflammatory Bowel disease. <i>GastroenterologÅa Y HepatologÅa</i> , 2021, 44, 312-319.	0.2	11
305	Evaluation of anti-TNF therapeutic response in patients with inflammatory bowel disease: Current and novel biomarkers. <i>EBioMedicine</i> , 2021, 66, 103329.	2.7	48
306	Prediction of Relapse After Antiâ€”Tumor Necrosis Factor Cessation in Crohnâ€™s Disease: Individual Participant Data Meta-analysis of 1317 Patients From 14 Studies. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1671-1686.e16.	2.4	15

#	ARTICLE	IF	CITATIONS
307	Predictive Value of Bowel Ultrasound in Crohn's Disease: A 12-Month Prospective Study. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e723-e740.	2.4	30
308	Treat-to-target approach in the management of inflammatory Bowel disease. <i>Gastroenterology &amp; Hepatology (English Edition)</i> , 2021, 44, 312-319.	0.0	0
309	Integrating a treat to target approach into clinical practice in 2020. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 6-7.	1.4	0
310	Endoscopic and histologic endpoints as treatment targets: Are we there yet?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 8-9.	1.4	0
311	What are the treatment targets in inflammatory bowel disease (IBD) in 2020?: Session one summary. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 4-5.	1.4	1
312	STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. <i>Gastroenterology</i> , 2021, 160, 1570-1583.	0.6	1,054
313	IBD 2020: Right therapy, right patient, right time – Choosing wisely: Conclusions. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 35-36.	1.4	0
314	A Microsimulation Model to Determine the Cost-Effectiveness of Treat-to-Target Strategies for Crohn's Disease. <i>American Journal of Gastroenterology</i> , 2021, 116, 1709-1719.	0.2	4
315	Control Crohn Safe with episodic adalimumab monotherapy as first-line treatment study (CoCroS): study protocol for a randomised controlled trial. <i>BMJ Open</i> , 2021, 11, e042885.	0.8	0
316	Patient Perspectives and Expectations in Inflammatory Bowel Disease: A Systematic Review. <i>Digestive Diseases and Sciences</i> , 2022, 67, 1956-1974.	1.1	17
317	Clinical, biomarker and endoscopic outcomes in patients with Crohn's disease treated with Ustekinumab: Multi-centre real world study. <i>GastroHep</i> , 2021, 3, 151-160.	0.3	0
318	Leucine-rich alpha-2 glycoprotein is a potential biomarker to monitor disease activity in inflammatory bowel disease receiving adalimumab: PLANET study. <i>Journal of Gastroenterology</i> , 2021, 56, 560-569.	2.3	34
319	Methodology and Initial Results From a Real-World Observational Cohort of Patients With Inflammatory Bowel Disease: TARGET-IBD. <i>Crohn's &amp; Colitis 360</i> , 2021, 3, .	0.5	3
320	International consensus on methodological issues in standardization of fecal calprotectin measurement in inflammatory bowel diseases. <i>United European Gastroenterology Journal</i> , 2021, 9, 451-460.	1.6	31
321	The Effectiveness and Safety of Hyperbaric Oxygen Therapy in Various Phenotypes of Inflammatory Bowel Disease: Systematic Review With Meta-analysis. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 611-621.	0.9	12
322	To Stop or Not to Stop? Predicting Relapse After Anti-TNF Cessation in Patients With Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1668-1670.	2.4	1
323	Early Laparoscopic Ileal Resection for Localized Ileocecal Crohn's Disease: Hard Sell or a Revolutionary New Norm?. <i>Inflammatory Intestinal Diseases</i> , 2022, 7, 13-20.	0.8	14
324	Histopathological Features in Colonic Biopsies at Diagnosis Predict Long-term Disease Course in Patients with Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 1885-1897.	0.6	2

#	ARTICLE	IF	CITATIONS
325	Treating inflammatory bowel diseases in the 21 <sup>st</sup> century: individualized therapy and telemedicine. <i>Vnitřní Lekarství</i> , 2021, 67, 201-205.	0.1	1
326	Experiencia de la vida real con el uso de mesalazina MMX en pacientes mexicanos con CUCI en dos centros de tercer nivel. <i>Revista De Gastroenterología De México</i> , 2021, , .	0.4	0
327	Patient Adherence to Fecal Calprotectin Testing Is Low Compared to Other Commonly Ordered Tests in Patients With Inflammatory Bowel Disease. <i>Crohn's &amp; Colitis</i> 360, 2021, 3, .	0.5	2
328	Biomarkers in diagnosis of IBD: yesterday, today, tomorrow. <i>Medical Alphabet</i> , 2021, 1, 14-18.	0.0	0
329	Systematic review: efficacy of escalated maintenance anti-tumour necrosis factor therapy in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 249-266.	1.9	9
330	Noninvasive Monitoring After Azathioprine Withdrawal in Patients With Inflammatory Bowel Disease in Deep Remission. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2293-2301.e1.	2.4	3
331	Microsimulation Model to Determine the Cost-Effectiveness of Treat-to-Target Strategies for Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1170-1179.e10.	2.4	5
332	The comparison of the three assays for determination of fecal calprotectin in inflammatory bowel disease. <i>Biochimica Medica</i> , 2021, 31, 295-301.	1.2	1
333	Monitoring established Crohn's disease with pan-intestinal video capsule endoscopy in Europe: clinician consultation using the nominal group technique. <i>Current Medical Research and Opinion</i> , 2021, 37, 1547-1554.	0.9	3
334	A new way to assess the trajectory of remission in Crohn's disease: Correlating drug levels with a non-invasive blood-biomarker of mucosal remission. <i>Crohn's &amp; Colitis</i> 360, 0, , .	0.5	0
335	Noninvasive Targeted Crohn Disease Management by Combining Endoscopic Healing Index and Therapeutic Drug Monitoring. <i>Crohn's &amp; Colitis</i> 360, 2021, 3, .	0.5	1
337	Systematic review: societal cost of illness of inflammatory bowel disease is increasing due to biologics and varies between continents. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 234-248.	1.9	47
338	AGA Technical Review on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn's Disease. <i>Gastroenterology</i> , 2021, 160, 2512-2556.e9.	0.6	44
339	Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists. <i>Gastroenterology</i> , 2021, 161, 47-65.	0.6	86
340	Real-life utility and diagnostic accuracy of a home-performed fecal calprotectin test to predict endoscopic activity in patients with inflammatory bowel disease under maintenance treatment with adalimumab. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, Publish Ahead of Print, .	0.8	1
341	Telehealth model of care for outpatient inflammatory bowel disease care in the setting of the COVID-19 pandemic. <i>Internal Medicine Journal</i> , 2021, 51, 1038-1042.	0.5	19
342	Fecal microbiota transplantation therapy in Crohn's disease: Systematic review. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 2672-2686.	1.4	35
343	Endoscopic Prediction of Crohn's Disease Postoperative Recurrence. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 680-688.	0.9	13

#	ARTICLE	IF	CITATIONS
344	Twenty-five years of biologics in IBD: What's all the hype about?. <i>Journal of Internal Medicine</i> , 2021, 290, 806-825.	2.7	15
345	Quality of life in patients with IBD during the COVID-19 pandemic in the Netherlands. <i>BMJ Open Gastroenterology</i> , 2021, 8, e000670.	1.1	7
346	Transmural healing as a therapeutic goal in Crohn's disease: a systematic review. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 659-667.	3.7	57
347	Designing Consumer Health Information Technology to Support Biform and Articulation Work: A Qualitative Study of Diet and Nutrition Management as Patient Work. <i>JMIR Human Factors</i> , 2021, 8, e27452.	1.0	3
348	Epidemiology of Colorectal Cancer in Inflammatory Bowel Disease – the Evolving Landscape. <i>Current Gastroenterology Reports</i> , 2021, 23, 16.	1.1	13
349	E – Health and remote management of patients with inflammatory bowel disease: lessons from Denmark in a time of need. <i>Internal Medicine Journal</i> , 2021, 51, 1207-1211.	0.5	5
350	Editorial: does anti-TNF treatment persistence always equate to effective treatment? Only objective disease assessments can answer the question. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 720-721.	1.9	0
351	Precision medicine and inflammatory bowel diseases: concept, strategies, future. <i>Ekspiermental'naya I Klinicheskaya Gastroenterologiya</i> , 2021, 1, 121-129.	0.1	1
352	Systematic Review and Meta-Analysis: Risk of Hospitalization in Patients with Ulcerative Colitis and Crohn's Disease in Population-Based Cohort Studies. <i>Digestive Diseases and Sciences</i> , 2022, 67, 2451-2461.	1.1	12
353	Assessing adherence to objective disease monitoring and outcomes with adalimumab in a real-world IBD cohort. <i>Digestive and Liver Disease</i> , 2021, 53, 980-986.	0.4	2
354	Early Diagnosis, Early Stratification, and Early Intervention to Deliver Precision Medicine in IBD. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 1254-1264.	0.9	27
355	Development of antifibrotic therapy for stricturing Crohn's disease: lessons from randomized trials in other fibrotic diseases. <i>Physiological Reviews</i> , 2022, 102, 605-652.	13.1	31
356	Newer Biologic and Small-Molecule Therapies for Inflammatory Bowel Disease. <i>New England Journal of Medicine</i> , 2021, 385, 1302-1315.	13.9	137
357	Management of Crohn Disease. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 69.	3.8	134
359	Cost-effectiveness of Telemedicine-directed Specialized vs Standard Care for Patients With Inflammatory Bowel Diseases in a Randomized Trial. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1744-1752.	2.4	49
360	Clinical trial results – A closer look under the surface. <i>European Journal of Internal Medicine</i> , 2020, 75, 21-22.	1.0	1
361	Clinical Performance of a Novel LIAISON Fecal Calprotectin Assay for Differentiation of Inflammatory Bowel Disease From Irritable Bowel Syndrome. <i>Journal of Clinical Gastroenterology</i> , 2021, 55, 239-243.	1.1	10
362	Use of Small Bowel Ultrasound to Predict Response to Infliximab Induction in Pediatric Crohn's Disease. <i>Journal of Clinical Gastroenterology</i> , 2021, 55, 429-432.	1.1	16

#	ARTICLE	IF	CITATIONS
363	Machine learning identifies novel blood protein predictors of penetrating and stricturing complications in newly diagnosed paediatric Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 281-290.	1.9	23
364	Chronic opioid use is associated with early biologic discontinuation in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 704-711.	1.9	7
365	Precision medicine in inflammatory bowel disease: concept, progress and challenges. <i>F1000Research</i> , 2020, 9, 54.	0.8	59
366	BIOLOGICAL THERAPY PENETRATION FOR INFLAMMATORY BOWEL DISEASE IN LATIN AMERICA: CURRENT STATUS AND FUTURE CHALLENGES. <i>Arquivos De Gastroenterologia</i> , 2019, 56, 318-322.	0.3	12
367	Are We Ready to Include Prognostic Factors in Inflammatory Bowel Disease Trials?. <i>Current Pharmaceutical Design</i> , 2019, 25, 64-68.	0.9	7
368	“Treat to Target”™ in Mild to Moderate Ulcerative Colitis: Evidence to Support this Strategy. <i>Current Drug Targets</i> , 2020, 22, 117-125.	1.0	3
369	A Concise History of Thiopurines for Inflammatory Bowel Disease: From Anecdotal Reporting to Treat-to-Target Algorithms. <i>Reviews on Recent Clinical Trials</i> , 2019, 14, 4-9.	0.4	15
370	Digital Health Apps in the Clinical Care of Inflammatory Bowel Disease: Scoping Review. <i>Journal of Medical Internet Research</i> , 2019, 21, e14630.	2.1	62
371	Precision medicine for pediatric inflammatory bowel disease: a perspective. <i>Precision and Future Medicine</i> , 2020, 4, 43-52.	0.5	2
372	Positioning of old and new biologicals and small molecules in the treatment of inflammatory bowel diseases. <i>World Journal of Gastroenterology</i> , 2018, 24, 3567-3582.	1.4	34
373	Consecutive fecal calprotectin measurements for predicting relapse in pediatric Crohn's™ disease patients. <i>World Journal of Gastroenterology</i> , 2019, 25, 1266-1277.	1.4	24
374	Combined evaluation of biomarkers as predictor of maintained remission in Crohn's™ disease. <i>World Journal of Gastroenterology</i> , 2019, 25, 2354-2364.	1.4	13
375	Individualized home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended in clinical practice: A randomized-clinical trial. <i>World Journal of Gastroenterology</i> , 2019, 25, 6158-6171.	1.4	15
376	Disease monitoring strategies in inflammatory bowel diseases: What do we mean by “tight control”™?. <i>World Journal of Gastroenterology</i> , 2019, 25, 6172-6189.	1.4	31
377	Functional gastrointestinal disorders in inflammatory bowel disease: Time for a paradigm shift?. <i>World Journal of Gastroenterology</i> , 2020, 26, 3712-3719.	1.4	17
378	First United Arab Emirates consensus on diagnosis and management of inflammatory bowel diseases: A 2020 Delphi consensus. <i>World Journal of Gastroenterology</i> , 2020, 26, 6710-6769.	1.4	12
379	Benefits of implementing a rapid access clinic in a high-volume inflammatory bowel disease center: Access, resource utilization and outcomes. <i>World Journal of Gastroenterology</i> , 2020, 26, 759-769.	1.4	8
380	Fecal lactoferrin accurately reflects mucosal inflammation in inflammatory bowel disease. <i>World Journal of Gastrointestinal Pathophysiology</i> , 2019, 10, 54-63.	0.5	13

#	ARTICLE	IF	CITATIONS
381	2019 Expert opinion on biological treatment use in inflammatory bowel disease management. Turkish Journal of Gastroenterology, 2020, 30, S913-S946.	0.4	3
382	Experience of patients with inflammatory bowel disease in using a home fecal calprotectin test as an objective reported outcome for self-monitoring. Intestinal Research, 2018, 16, 546-553.	1.0	21
383	Improving the quality of care for inflammatory bowel disease. Intestinal Research, 2019, 17, 45-53.	1.0	17
384	Clinical management for small bowel of Crohn's disease in the treat-to-target era: now is the time to optimize treatment based on the dominant lesion. Intestinal Research, 2020, 18, 347-354.	1.0	22
385	Medical Management of Crohn's Disease. Cureus, 2020, 12, e8351.	0.2	15
386	Mitochondria and Inflammatory Bowel Diseases: Toward a Stratified Therapeutic Intervention. Annual Review of Physiology, 2022, 84, 435-459.	5.6	40
387	IBD Disability Index Is Associated With Both Direct and Indirect Costs of Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2022, 28, 1189-1197.	0.9	3
388	Mucosal Healing in Crohn's Disease: Bull's Eye or Bust? The "Relative" Con Position. Inflammatory Intestinal Diseases, 2022, 7, 1-8.	0.8	1
389	Perception and clinical decisions from inflammatory bowel diseases' specialists towards positioning of new therapies in Crohn's disease and ulcerative colitis: A national web-based survey from the Brazilian IBD study group (GEDIIB). Gastroenterology & Hepatology, 2022, 45, 499-506.	0.2	0
390	Post-Induction High Adalimumab Drug Levels Predict Biological Remission at Week 24 in Patients With Crohn's Disease. Clinical and Translational Gastroenterology, 2021, 12, e00401.	1.3	5
391	Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis. The Lancet Gastroenterology and Hepatology, 2021, 6, 1002-1014.	3.7	114
393	Conventional and biological therapy for inflammatory bowel disease. Vnitřní Lekarství, 2018, 64, 642-653.	0.1	1
394	DIAMOND study: an additional evidence of the interest of being proactive in IBD. Annals of Translational Medicine, 2018, 6, 279-279.	0.7	0
395	Management of de Novo Crohn's Disease after Reconstructive Surgery with Continent Ileostomy in Ulcerative Colitis. , 2019, , 143-165.		0
396	Toward Personalized Therapy in Inflammatory Bowel Disease. , 2019, , 381-389.		0
397	Clinical Trial Design to Facilitate Biomarker Discovery. , 2019, , 45-53.		0
399	Anti-TNF combination therapy in inflammatory bowel disease: de novo or selective?. Minerva Gastroenterologica E Dietologica, 2020, 65, 291-297.	2.2	2
400	Strengthened monitoring and optimized management of Crohn's disease patients. World Chinese Journal of Digestology, 2020, 28, 660-668.	0.0	0



#	ARTICLE	IF	CITATIONS
401	Precision Medicine in Pediatric Inflammatory Bowel Disease. <i>Pediatric Clinics of North America</i> , 2021, 68, 1171-1190.	0.9	4
402	Therapeutic drug monitoring with vedolizumab in inflammatory bowel disease. <i>Minerva Gastroenterologica E Dietologica</i> , 2020, 65, 280-290.	2.2	4
403	Editorial: Gastrointestinal 2020: Novel inflammatory bowel disease treatments and therapeutic drug monitoring. <i>Current Opinion in Pharmacology</i> , 2020, 55, iii-vi.	1.7	0
404	Impact of intestinal ultrasound with a portable system in the management of Crohn's disease. <i>Gastroenterology Report</i> , 2021, 9, 418-426.	0.6	3
405	Therapeutic Drug Monitoring of Biologics for Patients with Inflammatory Bowel Diseases: How, When, and for Whom?. <i>Gut and Liver</i> , 2022, 16, 515-524.	1.4	6
406	Efficacy of anti-TNF dosing interval lengthening in adolescents and young adults with inflammatory bowel disease in sustained remission (FREE-study): protocol for a partially randomised patient preference trial. <i>BMJ Open</i> , 2021, 11, e054154.	0.8	5
407	Mucosal Healing in Crohn's Disease: Bull's Eye or Bust? – The Pro Position. <i>Inflammatory Intestinal Diseases</i> , 2022, 7, 36-41.	0.8	1
408	Effects of JAK1-Preferential Inhibitor Filgotinib on Circulating Biomarkers and Whole Blood Genes/Pathways of Patients With Moderately to Severely Active Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 1207-1218.	0.9	6
410	Guía de práctica clínica para el tratamiento de la enfermedad de Crohn en población adulta. <i>Revista Colombiana De Gastroenterología</i> , 2020, 35, 63-200.	0.1	3
411	The MARVEL trial: a phase 2b randomised placebo-controlled trial of oral MitoQ in moderate ulcerative colitis. <i>Immunotherapy Advances</i> , 2021, 1, .	1.2	6
412	A Noninvasive Method to Assess Mucosal Healing in Patients* With Crohn's Disease. <i>Gastroenterology and Hepatology</i> , 2018, 14, 1-12.	0.2	3
413	Targeting Mucosal Healing in Crohn's Disease. <i>Gastroenterology and Hepatology</i> , 2019, 15, 529-538.	0.2	4
414	Development of a Software for Treat-To-Target Strategy Implementation and Increasing Quality of Life in Patients with Inflammatory Bowel Disease. <i>Current Health Sciences Journal</i> , 2020, 46, 103-110.	0.2	1
416	Guidelines for the management of patients with Crohn's disease. Recommendations of the Polish Society of Gastroenterology and the Polish National Consultant in Gastroenterology. <i>Przegląd Gastroenterologiczny</i> , 2021, 16, 257-296.	0.3	10
417	Crohn's Disease. , 2022, , 379-391.		0
418	Digital Health Technologies for Remote Monitoring and Management of Inflammatory Bowel Disease: A Systematic Review. <i>American Journal of Gastroenterology</i> , 2022, 117, 78-97.	0.2	22
419	Factors associated with time to clinical remission in pediatric luminal Crohn's disease: A retrospective cohort study. <i>JGH Open</i> , 2021, 5, 1373-1381.	0.7	4
420	Fecal Calprotectin Is Increased in Pouchitis and Progressively Increases With More Severe Endoscopic and Histologic Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1839-1846.e2.	2.4	7

#	ARTICLE	IF	CITATIONS
421	Long-Term Outcomes With Adalimumab Therapy in Pediatric Crohn Disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2022, 74, 389-395.	0.9	7
422	Unmet needs in inflammatory bowel disease. <i>Current Research in Pharmacology and Drug Discovery</i> , 2021, 2, 100070.	1.7	8
423	Real-world experience with MMX mesalazine use in Mexican patients with ulcerative colitis at two tertiary care centers. <i>Revista De Gastroenterología De México (English Edition)</i> , 2021, , .	0.1	0
424	Induction of Remission in Pediatric Crohn's Disease Patients Assessed by the Mucosal Inflammation Noninvasive Index. <i>Journal of Clinical Medicine</i> , 2021, 10, 5613.	1.0	5
425	From single-target to cellular niche targeting in Crohn's disease: intercepting bad communications. <i>EBioMedicine</i> , 2021, 74, 103690.	2.7	3
426	Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110599.	1.4	16
427	Evolving Short- and Long-Term Goals of Management of Inflammatory Bowel Diseases: Getting It Right, Making It Last. <i>Gastroenterology</i> , 2022, 162, 1424-1438.	0.6	26
428	Can 2 Different Fecal Calprotectin Assays be Used Interchangeably in IBD Treatment?. <i>Journal of Clinical Gastroenterology</i> , 2022, 56, e27-e30.	1.1	0
429	Recent advances in clearance monitoring of monoclonal antibodies in patients with inflammatory bowel diseases. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 1455-1466.	1.3	10
430	What Does Disease Progression Look Like in Ulcerative Colitis, and How Might It Be Prevented?. <i>Gastroenterology</i> , 2022, 162, 1396-1408.	0.6	49
431	Point-of-Care Testing and Home Testing: Pragmatic Considerations for Widespread Incorporation of Stool Tests, Serum Tests, and Intestinal Ultrasound. <i>Gastroenterology</i> , 2022, 162, 1476-1492.	0.6	19
432	Cost-Effectiveness of Tight Control for Crohn's Disease With Adalimumab-Based Treatment: Economic Evaluation of the CALM Trial From a Canadian Perspective. <i>Journal of the Canadian Association of Gastroenterology</i> , 2022, 5, 169-176.	0.1	5
433	Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era. <i>Advances in Therapy</i> , 2022, 39, 2342-2364.	1.3	10
434	Disease Monitoring in Inflammatory Bowel Disease: Evolving Principles and Possibilities. <i>Gastroenterology</i> , 2022, 162, 1456-1475.e1.	0.6	38
435	Using MR Enterography and CT Enterography for Routine Crohn's Surveillance: How We Do It Now, and How We Hope to Do it in the Future. <i>Korean Journal of Radiology</i> , 2022, 23, 1.	1.5	4
436	Circulating Dipeptidyl Peptidase Activity Is a Potential Biomarker for Inflammatory Bowel Disease. <i>Clinical and Translational Gastroenterology</i> , 2022, 13, e00452.	1.3	2
437	Crohn's disease therapeutic dietary intervention (CD-TDI): study protocol for a randomised controlled trial. <i>BMJ Open Gastroenterology</i> , 2022, 9, e000841.	1.1	0
438	Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 294-306.	3.7	42



#	ARTICLE	IF	CITATIONS
439	Treat to target with ustekinumab for Crohn's disease. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, , .	3.7	0
440	Intensive drug therapy versus standard drug therapy for symptomatic intestinal Crohn's disease strictures (STRIDENT): an open-label, single-centre, randomised controlled trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 318-331.	3.7	20
441	Risk Factors of Clinical Relapses in Pediatric Luminal Crohn's Disease: A Retrospective Cohort Study. <i>American Journal of Gastroenterology</i> , 2022, 117, 637-646.	0.2	4
442	Small bowel Crohn's disease: optimal modality for diagnosis and monitoring. <i>Current Opinion in Gastroenterology</i> , 2022, 38, 292-298.	1.0	1
443	Antitumour necrosis factor alpha treatment in Crohn's disease: long-term efficacy, side effects and need for surgery. <i>Scandinavian Journal of Gastroenterology</i> , 2022, , 1-9.	0.6	1
444	Objective disease activity assessment and therapeutic drug monitoring prior to biologic therapy changes in routine inflammatory bowel disease clinical practice: TARGET-IBD. <i>BMC Gastroenterology</i> , 2022, 22, 71.	0.8	3
446	The Relationship Between Opioid Use and Healthcare Utilization in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 1904-1914.	0.9	6
447	Prediction of Inflammatory Bowel Disease Course Based on Fecal Scent. <i>Sensors</i> , 2022, 22, 2316.	2.1	4
448	Earlier Anti-TNF Initiation Leads to Long-term Lower Health Care Utilization in Crohn's Disease but Not in Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2607-2618.e14.	2.4	13
449	Early sonographic response to a new medical therapy is associated with future treatment response or failure in patients with inflammatory bowel disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2022, 34, 613-621.	0.8	3
451	Impact of COVID-19 pandemic on pediatric endoscopy: A multicenter study on behalf of the SIGENP Endoscopy Working Group. <i>Digestive and Liver Disease</i> , 2022, 54, 572-579.	0.4	5
452	Intestinal ultrasonography and fecal calprotectin for monitoring inflammation of ileal Crohn's disease: two complementary tests. <i>Intestinal Research</i> , 2022, , .	1.0	4
453	De-escalation of biological therapy in inflammatory bowel disease patients following prior dose escalation. <i>European Journal of Gastroenterology and Hepatology</i> , 2022, Publish Ahead of Print, .	0.8	2
454	Complete endoscopic healing is associated with lower disability than partial endoscopic healing in Crohn's disease: A prospective multicenter study. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2022, 46, 101887.	0.7	4
455	Role of Biomarkers in the Diagnosis and Treatment of Inflammatory Bowel Disease. <i>Life</i> , 2021, 11, 1375.	1.1	15
456	A Clinical Prediction Model to Determine Probability of Response to Certolizumab Pegol for Crohn's Disease. <i>BioDrugs</i> , 2022, 36, 85-93.	2.2	2
457	Subclinical Persistent Inflammation as Risk Factor for Crohn's Disease Progression: Findings From a Prospective Real-World Study of 2 Years. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2059-2073.e7.	2.4	4
458	Transmural healing and MRI healing are associated with lower risk of bowel damage progression than endoscopic mucosal healing in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 577-586.	1.9	35

#	ARTICLE	IF	CITATIONS
459	Part I: Inflammatory bowel disease. JACCP Journal of the American College of Clinical Pharmacy, 2020, 3, 1514-1519.	0.5	0
460	SMALL BOWEL IS LARGELY AFFECTED IN BEHÇET'S DISEASE: A LONG-TERM FOLLOW-UP OF GASTROINTESTINAL SYMPTOMS. Arquivos De Gastroenterologia, 2022, 59, 117-122.	0.3	1
461	Correlation between ultrasonographic response and anti-tumor necrosis factor drug levels in Crohn's disease. Therapeutic Drug Monitoring, 2022, Publish Ahead of Print, .	1.0	2
464	Analysis of risk factors for early clinical recurrence of inflammatory bowel disease after fecal microbiota transplantation.. American Journal of Translational Research (discontinued), 2021, 13, 12875-12886.	0.0	1
465	C-reactive protein levels and prevalence of leukopenia in patients with inflammatory bowel disease treated with azathioprine and/or mesalazine: a real-life study. Einstein (Sao Paulo, Brazil), 2022, 20, eAO6500.	0.3	2
466	Therapy Patterns and Surveillance Measures of Inflammatory Bowel Disease Patients beyond Disease-Related Hospitalization: A Claims-Based Cohort Study. Inflammatory Intestinal Diseases, 2022, 7, 104-118.	0.8	0
467	Tools for the Diagnosis and Management of Crohn's Disease. Gastroenterology Clinics of North America, 2022, 51, 213-239.	1.0	2
468	Fecal S100A12 is associated with future hospitalization and step-up of medical treatment in patients with Crohn's disease in clinical remission: a pilot study. Intestinal Research, 2022, 20, 203-212.	1.0	2
469	Is it time to include older adults in inflammatory bowel disease trials? A call for action. The Lancet Healthy Longevity, 2022, 3, e356-e366.	2.0	14
470	The second decade of anti-TNF- $\alpha$ therapy in clinical practice: new lessons and future directions in the COVID-19 era. Rheumatology International, 2022, 42, 1493-1511.	1.5	22
471	Comparative Risk of Incident Cancer in Patients with Inflammatory Bowel Disease with Prior Non-digestive Malignancy According to Immunomodulator: a Multicentre Cohort Study. Journal of Crohn's and Colitis, 2022, 16, 1523-1530.	0.6	12
472	Proactive infliximab is more effective than vedolizumab in inducing fecal calprotectin remission in inflammatory bowel disease. Scandinavian Journal of Gastroenterology, 0, , 1-7.	0.6	1
473	The Impact of Intestinal Ultrasound on the Management of Inflammatory Bowel Disease: From Established Facts Toward New Horizons. Frontiers in Medicine, 2022, 9, .	1.2	5
474	Integrated Systematic Pharmacology Analysis and Experimental Validation to Reveal the Mechanism of Action of Semen Aesculi on Inflammatory Bowel Diseases. SSRN Electronic Journal, 0, , .	0.4	0
475	Serum leucine-rich alpha $2$ glycoprotein as a predictive factor of endoscopic remission in Crohn's disease. Journal of Gastroenterology and Hepatology (Australia), 2022, 37, 1741-1748.	1.4	3
476	The disease severity index for inflammatory bowel disease is associated with psychological symptoms and quality of life, and predicts a more complicated disease course. Alimentary Pharmacology and Therapeutics, 2022, 56, 664-674.	1.9	16
477	A Serum Biomarker Panel Can Accurately Identify Mucosal Ulcers in Patients With Crohn's Disease. Inflammatory Bowel Diseases, 2023, 29, 555-562.	0.9	3
478	Serum Monitoring of Recurrence in Post-Operative Crohn's Disease: Have We Arrived?. Journal of Crohn's and Colitis, 0, , .	0.6	3

#	ARTICLE	IF	CITATIONS
479	A hands-free stool sampling system for monitoring intestinal health and disease. <i>Scientific Reports</i> , 2022, 12, .	1.6	3
480	Formyl peptide receptor 2 as a potential therapeutic target for inflammatory bowel disease. <i>Acta Pharmacologica Sinica</i> , 0, , .	2.8	3
481	LIAISON <sup>Â®</sup> Calprotectin for the prediction of relapse inÂQuiescent ulcerative colitis: The EuReCa study. <i>United European Gastroenterology Journal</i> , 0, , .	1.6	2
482	Treat to transmural healing: how to incorporate intestinal ultrasound into the treatment of inflammatory bowel disease. <i>British Journal of Radiology</i> , 2022, 95, .	1.0	1
483	CORE-IBD: A Multidisciplinary International Consensus Initiative to Develop a Core Outcome Set for Randomized Controlled Trials in Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2022, 163, 950-964.	0.6	29
484	Global Hospitalization Trends for Crohnâ€™s Disease and Ulcerative Colitis in the 21st Century: A Systematic Review With Temporal Analyses. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 2211-2221.	2.4	37
485	Faecal Myeloperoxidase as a Biomarker of Endoscopic Activity in Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 1862-1873.	0.6	18
486	Editorial: measuring disease severity in inflammatory bowel diseaseâ€™the whole is greater than the sum of its parts. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 746-747.	1.9	0
487	Utilization of Colonoscopy Following Treatment Initiation in U.S. Commercially Insured Patients With Inflammatory Bowel Disease, 2013-2019. <i>Inflammatory Bowel Diseases</i> , 2023, 29, 735-743.	0.9	3
488	Therapeutic drug monitoring in inflammatory bowel disease: implementation, utilization, and barriers in clinical practice in Scandinavia. <i>Scandinavian Journal of Gastroenterology</i> , 2023, 58, 25-33.	0.6	3
489	Perception and clinical decisions from inflammatory bowel diseasesâ€™ specialists towards positioning of new therapies in Crohn's disease and ulcerative colitis: A national web-based survey from the Brazilian IBD study group (GEDIB). <i>GastroenterologÃa Y HepatologÃa (English Edition)</i> , 2022, 45, 499-506.	0.0	0
490	High Perceived Stress is Associated With Increased Risk of Ulcerative Colitis Clinical Flares. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 741-749.e3.	2.4	10
491	Integrated systematic pharmacology analysis and experimental validation to reveal the mechanism of action of Semen aesculi on inflammatory bowel diseases. <i>Journal of Ethnopharmacology</i> , 2022, 298, 115627.	2.0	3
492	Patient activation and its association with health indices among patients with inflammatory bowel disease. <i>Therapeutic Advances in Gastroenterology</i> , 2022, 15, 175628482211287.	1.4	2
493	Exploring the concept of deep remission in Crohnâ€™s disease: correlation between transmural healing and biomarkers. <i>Therapeutic Advances in Gastroenterology</i> , 2022, 15, 175628482211106.	1.4	4
494	Analysis of biomarkers and composite scores in IBD patients using probabilistic fuzzy systems. , 2022, , .		0
495	Optimized Infliximab Induction Predicts Better Longâ€™term Clinical and Biomarker Outcomes Compared to Standard Induction Dosing. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2022, 75, 601-607.	0.9	4
497	METRIC-EF: magnetic resonance enterography to predict disabling disease in newly diagnosed Crohnâ€™s diseaseâ€™ protocol for a multicentre, non-randomised, single-arm, prospective study. <i>BMJ Open</i> , 2022, 12, e067265.	0.8	3

#	ARTICLE	IF	CITATIONS
498	Oral administration of human carbonic anhydrase I suppresses colitis in a murine inflammatory bowel disease model. <i>Scientific Reports</i> , 2022, 12, .	1.6	2
499	Creation of an Inflammatory Bowel Disease Referral Pathway for Identifying Patients Who Would Benefit From Inflammatory Bowel Disease Specialist Consultation. <i>Inflammatory Bowel Diseases</i> , 0, , .	0.9	0
500	Effectiveness and Safety of Ustekinumab for Moderate to Severely Active Crohn's Disease: Results from an Early Access Program in Brazil. <i>Journal of Clinical Medicine</i> , 2022, 11, 6481.	1.0	3
501	Systematic Review and Meta-analysis: Loss of Response and Need for Dose Escalation of Infliximab and Adalimumab in Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2023, 29, 1633-1647.	0.9	8
502	Targeting Mucosal Healing: Optimising Results with Early Appropriate Therapy in Crohn's Disease. <i>European Medical Journal (Chelmsford, England)</i> , 0, , 52-57.	3.0	0
503	Are We Ready to Change the Course of Inflammatory Bowel Disease?. <i>European Medical Journal Gastroenterology</i> , 0, , 55-68.	0.0	0
504	Non-invasive monitoring and treatment-target approach are cost-effective in patients with mild-to-moderate ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2023, 57, 486-495.	1.9	5
505	De-escalation of Therapy in Patients with Quiescent Inflammatory Bowel Disease. <i>Gut and Liver</i> , 2022, , .	1.4	2
506	New <i>Lactobacillus plantarum</i> membrane proteins (LpMPs) towards oral anti-inflammatory agents against dextran sulfate sodium-induced colitis. <i>International Immunopharmacology</i> , 2022, 113, 109416.	1.7	0
507	Apports de lâ€™hypnose dans la prise en charge de la maladie de Crohn: intÃ©rÃ©ts et rÃ©sultats prÃ©liminaires de lâ€™Ã©tude HypnoCrohn. <i>HEGEL - HEpato-GastroEntÃ©rologie LibÃ©rale</i> , 2022, NÃ° 3, 199-212.	0.0	2
508	A scoping review on early inflammatory bowel disease: definitions, pathogenesis, and impact on clinical outcomes. <i>Therapeutic Advances in Gastroenterology</i> , 2022, 15, 175628482211426.	1.4	6
509	Factors Associated With Fecal Calprotectin Sample Collection Compliance: An IBD Center Quality Improvement Project. <i>Crohn's &amp; Colitis 360</i> , 2022, 4, .	0.5	0
510	<i>Panax notoginseng</i> Alleviates Colitis via the Regulation of Gut Microbiota. <i>The American Journal of Chinese Medicine</i> , 2023, 51, 107-127.	1.5	2
511	Capsule endoscopy in Crohn's disease surveillance: A monocentric, retrospective analysis in Italy. <i>Frontiers in Medical Technology</i> , 0, 4, .	1.3	2
512	Treatment-target and sequencing therapies in Crohn's disease. <i>United European Gastroenterology Journal</i> , 2022, 10, 1121-1128.	1.6	14
513	Patency Capsule: A Novel Independent Predictor for Long-Term Outcomes Among Patients With Quiescent Crohn's Disease. <i>American Journal of Gastroenterology</i> , 2023, 118, 1019-1027.	0.2	4
514	Serum Leucine-Rich Î±2 Glycoprotein: A Novel Biomarker for Transmural Inflammation in Crohn's Disease. <i>American Journal of Gastroenterology</i> , 2023, 118, 1028-1035.	0.2	5
516	Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2023, 8, 215-227.	3.7	24

#	ARTICLE	IF	CITATIONS
517	Advancing the precision management of inflammatory bowel disease in the era of omics approaches and new technology. <i>World Journal of Gastroenterology</i> , 0, 29, 272-285.	1.4	7
518	ECCO Topical Review on Biological Treatment Cycles in Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2023, 17, 1031-1045.	0.6	5
519	Big Data in Gastroenterology Research. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2458.	1.8	6
520	Nutritional interventions in adult fibrostenotic Crohn's disease: A systematic review. <i>Frontiers in Nutrition</i> , 0, 10, .	1.6	0
521	Efficacious dosing regimens for anti-TNF therapies in inflammatory bowel disease: where do we stand?. <i>Expert Opinion on Biological Therapy</i> , 2023, 23, 341-351.	1.4	1
522	Harnessing the Power of Precision Medicine and Novel Biomarkers to Treat Crohn's Disease. <i>Journal of Clinical Medicine</i> , 2023, 12, 2696.	1.0	3
523	The cost of inflammatory bowel disease in high-income settings: a Lancet Gastroenterology & Hepatology Commission. <i>The Lancet Gastroenterology and Hepatology</i> , 2023, 8, 458-492.	3.7	26
524	Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2023, 8, 307-320.	3.7	42
525	Serum N-Glycomic Biomarkers Predict Treatment Escalation in Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2023, 17, 919-932.	0.6	3
526	Cell-level systems biology model to study inflammatory bowel diseases and their treatment options. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2023, 12, 690-705.	1.3	1
527	Declining Enrolment and Other Challenges in IBD Clinical Trials: Causes and Potential Solutions. <i>Journal of Crohn's and Colitis</i> , 2023, 17, 1066-1078.	0.6	8
528	Mild Crohn's Disease: Definition and Management. <i>Current Gastroenterology Reports</i> , 2023, 25, 45-51.	1.1	2
529	Predictors and Etiologies of Clinical Relapse Among Patients With Ulcerative Colitis in Deep Remission. <i>Journal of Clinical Gastroenterology</i> , 2024, 58, 195-199.	1.1	0
530	Management of Inflammatory Bowel Disease in Patients with Current or Past Malignancy. <i>Cancers</i> , 2023, 15, 1083.	1.7	4
531	Treatment escalation and de-escalation decisions in Crohn's disease: Delphi consensus recommendations from Japan, 2021. <i>Journal of Gastroenterology</i> , 2023, 58, 313-345.	2.3	9
532	Editorial: treatment target in ulcerative colitis clinical management—a small price to pay? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2023, 57, 571-572.	1.9	0
533	Pretreatment serum monocyte chemoattractant protein-1 as a predictor of long-term outcome by ustekinumab in patients with Crohn's disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2023, 38, 910-920.	1.4	0
534	Neurotuberculosis in a Patient with Ulcerative Colitis Using Long-Term Adalimumab: A Rare Case. <i>American Journal of Case Reports</i> , 0, 24, .	0.3	1

#	ARTICLE	IF	CITATIONS
535	AGA Clinical Practice Guideline on the Role of Biomarkers for the Management of Ulcerative Colitis. <i>Gastroenterology</i> , 2023, 164, 344-372.	0.6	19
536	Fecal Markers in Inflammatory Bowel Disease. , 2023, , 245-253.		0
537	Infliximab Therapy for Pediatric Crohn Disease and Ulcerative Colitis. , 2023, , 407-422.		0
538	Anti-TNF Therapies Other Than Infliximab for the Treatment of Pediatric Inflammatory Bowel Disease. , 2023, , 423-443.		0
539	Precision medicine in inflammatory bowel disease: Individualizing the use of biologics and small molecule therapies. <i>World Journal of Gastroenterology</i> , 0, 29, 1395-1406.	1.4	0
540	A Systematic Review on Long-Term Efficacy Outcome Measures in Crohn's Disease Patients. <i>Journal of Crohn's and Colitis</i> , 2023, 17, 1528-1536.	0.6	2
541	Hospitalization Rates for Inflammatory Bowel Disease Are Decreasing Over Time: A Population-based Cohort Study. <i>Inflammatory Bowel Diseases</i> , 0, , .	0.9	0
542	Precision medicine in inflammatory bowel disease: Individualizing the use of biologics and small molecule therapies. <i>World Journal of Gastroenterology</i> , 0, 29, 1539-1550.	1.4	2
543	Dose Escalation Patterns of Advanced Therapies in Crohn's Disease and Ulcerative Colitis: A Systematic Literature Review. <i>Advances in Therapy</i> , 2023, 40, 2051-2081.	1.3	5
544	Low Adherence is Associated with Chronic Active Disease in Ulcerative Colitis: A Retrospective Study from a Single Referral Center. <i>Patient Preference and Adherence</i> , 0, Volume 17, 807-816.	0.8	2
545	Recent Advances in the Optimization of Anti-TNF Treatment in Patients with Inflammatory Bowel Disease. <i>Journal of Clinical Medicine</i> , 2023, 12, 2452.	1.0	1
546	Longitudinal Fecal Calprotectin Profiles Characterize Disease Course Heterogeneity in Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 2918-2927.e6.	2.4	2
547	Correlation of Ultrasound Scores with Endoscopic Activity in Crohn's Disease: A Prospective Exploratory Study. <i>Journal of Crohn's and Colitis</i> , 2023, 17, 1387-1394.	0.6	6
548	Personalize, participate, predict, and prevent: 4Ps in inflammatory bowel disease. <i>Frontiers in Medicine</i> , 0, 10, .	1.2	3
549	Utilization of Treat-to-Target Monitoring Colonoscopy After Treatment Initiation in the US-Based Study of a Prospective Adult Research Cohort With Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 2023, 118, 1638-1647.	0.2	4
565	Review article: Translating STRIDE into clinical reality – Opportunities and challenges. <i>Alimentary Pharmacology and Therapeutics</i> , 2023, 58, 492-502.	1.9	11
582	Editorial: If STRIDE is the hammer, then Crohn's disease and ulcerative colitis are not the same nails. <i>Alimentary Pharmacology and Therapeutics</i> , 2023, 58, 632-633.	1.9	1
627	Predictive, preventive and personalised approach as a conceptual and technological innovation in primary and secondary care of inflammatory bowel disease benefiting affected individuals and populations. <i>EPMA Journal</i> , 2024, 15, 111-123.	3.3	0

#	ARTICLE	IF	CITATIONS
---	---------	----	-----------